Sleep is an essential homeostatically-regulated state of decreased activity and alertness 103 conserved across animal species, and both short and long sleep duration associate with 104 chronic disease and all-cause mortality 1,2 . Defining genetic contributions to sleep 105 duration could point to regulatory mechanisms and clarify causal disease relationships. 106
In the childhood/adolescent GWAS for sleep duration from the EAGLE consortium 28 
Appendix 1). 205 206
Given the limitations of self-reported sleep duration
32,33 , we tested the 78 lead variants 207 for association with 8 accelerometer-derived sleep estimates in a subgroup who had 208 completed up to 7 days of wrist-worn accelerometry (n =85,499; Supplementary Table14) 34 . The lead PAX8 genetic variant was associated with 2.68 (0.29) min longer sleep 210 duration (compared to 2.44 (0.16) min by self-report), 0.21 (0.04) % greater sleep 211 efficiency, and 0.94 (0.23) min greater daytime inactivity duration per minor A allele (P 212 <0.00064; Supplementary Table 15 ). The 5% of participants carrying the most of the 213 78 sleep duration-increasing alleles were estimated to have 9.7 [7.5-11.8] min longer 214 sleep duration compared to the 5% carrying the fewest. The 78 SNP GRS associated 215 with longer accelerometer-derived sleep duration, longer duration of daytime inactivity, 216 greater sleep efficiency, and larger number of sleep bouts, but not with day-to-day 217 variability in sleep duration or estimates of sleep timing ( Table 1) . A GRS of 27 short 218 sleep variants was associated with shorter accelerometer-derived sleep duration, lower 219 sleep efficiency and fewer sleep bouts, whereas a GRS of 8 long sleep variants 220 associated with longer accelerometer-derived sleep duration, higher sleep efficiency, 221 and longer daytime inactivity ( Online Methods: 315
Population and study design 316
Study participants were from the UK Biobank study, described in detail elsewhere 51 . In 317 brief, the UK Biobank is a prospective study of >500,000 people living in the United 318
Kingdom. All people in the National Health Service registry who were aged 40-69 and 319 living <25 miles from a study center were invited to participate between 2006-2010. In 320 total 503,325 participants were recruited from over 9.2 million invitations. Extensive 321 phenotypic data were self-reported upon baseline assessment by participants using 322 touchscreen tests and questionnaires and at nurse-led interviews. Anthropometric 323 assessments were also conducted and health records were obtained from secondary 324 care data from linked Hospital episode statistics (HES) obtained up until 04/2017. Forthe current analysis, 24,533 individuals of non-white ethnicity (as defined in "Genotyping 326 and quality control") were excluded to avoid confounding effects. 327 328
Sleep duration and covariate measures 329
Study participants (n ~500,000) self-reported sleep duration at baseline assessment. 330
Participants were asked, "About how many hours sleep do you get in every 24 hours? 331 (please include naps)," with responses in hour increments. Sleep duration was treated 332 as a continuous variable and also categorized as either short (6 hours or less), normal 333 (7 or 8 hours), or long (9 hours or more) sleep duration. Extreme responses of less than 334 3 hours or more than 18 hours were excluded 23 and "Do not know" or "Prefer not to 335
answer" responses were set to missing. Participants who self-reported any sleep 336 medication (see Supplementary Method 1) were excluded. Furthermore, participants 337 who self-reported any shift work or night shift work or those with prevalent chronic 338 disease (i.e., breast, prostate, bowel or lung cancer, heart disease or stroke) or 339 psychiatric disorders (see Supplementary Method 2) were later additionally excluded 340 in a secondary GWAS. 341
Participants further self-reported age, sex, caffeine intake (self-reported cups of 342 tea per day and cups of coffee per day), daytime napping ("Do you have a nap during 343 the day?"), smoking status, alcohol intake frequency (never, once/week, 2-3 344 times/week, 4-6 times/week, daily), menopause status, and employment status during 345 assessment. Socio-economic status was represented by the Townsend deprivation 346 index based on national census data immediately preceding participation in the UK 347
Biobank. Weight and height were measured and body-mass index (BMI) was calculated 348 as weight (kg) / height 2 (m 2 ). Cases of sleep apnea were determined from self-report 349 during nurse-led interviews or health records using International Classification of 350 Diseases (ICD)-10 codes for sleep apnea (G47.3). Cases of insomnia were determined 351 from self-report to the question, "Do you have trouble falling asleep at night or do you 352 wake up in the middle of the night?" with responses "never/rarely", "sometimes", 353
"usually", "prefer not to answer". Participants who responded "usually" were set as 354 insomnia cases, and remaining participants were set as controls. Missing covariates 355
were imputed by using sex-specific median values for continuous variables (i.e., BMI, 356 caffeine intake, alcohol intake, and Townsend index), or using a missing indicator 357 approach for categorical variables (i.e., napping, smoking, menopause, and 358 employment). 359 360
Activity-monitor derived measures of sleep 361
Actigraphy devices (Axivity AX3) were worn 2.8 -9.7 years after study baseline by 362 103,711 individuals from the UK Biobank for up to 7 days. Details are described 363 excluded. 85,502 samples remained after non-white ethnicity exclusions. Sleep 372 measures were derived by processing raw accelerometer data (.cwa). First we 373 converted .cwa files available from the UK Biobank to .wav files using Omconvert 374 (https://github.com/digitalinteraction/openmovement/tree/master/Software/AX3/omconve 375 rt ) for signal calibration to gravitational acceleration 52,53 and interpolation 52 . The .wav 376 files were processed with the R package GGIR to infer activity monitor wear time 54 , and 377 extract the z-angle across 5-second epoch time-series data for subsequent use in 378 estimating the sleep period time window (SPT-window) 34 and sleep episodes within it 55 . 379
The SPT-window was estimated using an algorithm described in 34 active ten hours (M10) of each day were defined using a five-hour and ten-hour daily 398 period of minimum and maximum activity, respectively. These periods were estimated 399 using a rolling average of the respectively time window. L5 was defined as the number 400 of hours elapsed from the previous midnight whereas M10 was defined as the number 401 of hours elapsed from the previous midday. Genetic risk scores for sleep duration, short sleep and long sleep were tested using the 411 weighted genetic risk score calculated by summing the products of the sleep trait risk 412 allele count for all 78, 27, or 8 genome-wide significant SNPs multiplied by the scaled 413 effect from the primary GWAS using the GTX package in R 56 . 414
415

Genotyping and quality control 416
Phenotype data is available for 502,631 subjects in the UK Biobank. Genotyping was 417 performed by the UK Biobank, and genotyping, quality control, and imputation 418 procedures are described in detail here 57 . In brief, blood, saliva, and urine was collected 419 from participants, and DNA was extracted from the buffy coat samples. Participant DNAwas genotyped on two arrays, UK BiLEVE and UK Biobank Axiom with >95% common 421 content and genotypes for ~800,000 autosomal SNPs were imputed to two reference 422 panels. Genotypes were called using Affymetrix Power Tools software. Sample <95% for all tests). For each batch (106 batches total) markers that failed at least one 434 test were set to missing. Before imputation, 805,426 SNPs pass QC in at least one 435 batch (>99% of the array content). Population structure was captured by principal 436 component analysis on the samples using a subset of high quality (missingness <1.5%), 437 high frequency SNPs (>2.5%) (~100,000 SNPs) and identified the sub-sample of white 438 British descent. We further clustered subjects into four ancestry clusters using K-means 439 clustering on the principal components, identifying 453,964 subjects of European 440 ancestry. Imputation of autosomal SNPs was performed centrally by the UK Biobank to 441 UK10K haplotype, 1000 Genomes Phase 3, and Haplotype Reference Consortium 442 (HRC) with the current analysis using only those SNPs imputed to the HRC referencepanel. Autosomal SNPs were pre-phased using SHAPEIT3 58 and imputed using 444 IMPUTE4. In total ~96 million SNPs were imputed. Related individuals were identified 445 by estimating kinship coefficients for all pairs of samples, using only markers weakly 446 informative of ancestral background. In total there are 107,162 related pairs comprised 447 of 147,731 individuals related to at least one other participants in the UK Biobank. 448 449
Genome-wide association analysis 450
Genetic association analysis was performed in related subjects of European ancestry (n 451 GenABEL in R 56 , and estimated values were consistent with those estimated for other 467 highly polygenic complex traits. Additional independent risk loci were identified using the 468 approximate conditional and joint association method implemented in GCTA (GCTA-469 COJO) 60 . 470 471
Post-GWAS analyses 472
Sensitivity analyses of top signals 473
Follow-up analyses on genome-wide significant loci in the primary analyses included 474 covariate sensitivity analyses adjusting for BMI, insomnia, or caffeine intake 475 adjustments individually, or a combined adjustment for BMI, day naps, Townsend index, 476 smoking, alcohol intake, menopause status, employment status, and sleep apnea in 477 addition to baseline adjustments for age, sex, 10 principal components of ancestry, and 478 genotyping array. Sensitivity analyses were performed in PLINK 1.9 59 using 479 linear/logistic regression conducted only in unrelated subjects of white British ancestry. 480
481
Replication and meta-analyses with self-reported sleep duration GWAS 482
Using publicly available databases, we conducted a lookup of lead self-reported sleep 483 duration signals in self-reported sleep duration GWAS results from adult (CHARGE) and 484 childhood/adolescent (EAGLE). If lead signal was unavailable, a proxy SNP was used 485
instead. In addition, we combined self-reported sleep duration GWAS results from adult 486 (CHARGE) and childhood/adolescent (EAGLE) with the UK Biobank (primary model) in 487 fixed-effects meta-analyses using the inverse variance-weighted method in METAL 61 . 488
Meta-analyses were conducted first separately [UK Biobank + CHARGE (n=3,044,490 489 variants) or UK Biobank + EAGLE (n=7,147,509 variants)], then combined (UK Biobank 490 + CHARGE + EAGLE; n=2,545,157 variants). A genetic risk score for sleep durationwas tested using the weighted genetic risk score calculated by summing the products of 492 the sleep duration risk allele count for as many available SNPs of the 78 genome-wide 493 significant SNPs in each study (70 for CHARGE, 77 for EAGLE) multiplied by the scaled 494 effect from the primary GWAS using the GTX package in R 56 .
Gene, pathway and tissue-enrichment analyses 499
Gene-based analysis was performed using Pascal 39 . Pascal gene-set enrichment 500 analysis uses 1,077 pathways from KEGG, REACTOME, BIOCARTA databases, and a 501 significance threshold was set after Bonferroni correction accounting for 1,077 pathways 502 tested (P <0.05/1,077). Pathway analysis was also conducted using MAGMA 38 gene-503 set analysis in FUMA 62 , which uses the full distribution of SNP P values and is 504 performed for curated gene sets and GO terms obtained from MsigDB (total of 10,891 505 pathways). A significance threshold was set after Bonferroni correction accounting for 506 all pathways tested (P <0.05/10,891). Tissue enrichment analysis was conducted using 507 FUMA 62 for 53 tissue types, and a significance threshold was set following Bonferroni 508 correction accounting for all tested tissues (P <0.05/53). Integrative transcriptome-wide 509 association analyses with GWAS were performed using the FUSION TWAS package 44 510 with weights generated from gene expression in 9 brain regions and 2 tissues from the 511 GTEx consortium (v6). Tissues for TWAS testing were selected from the FUMA tissue 512 enrichment analyses and here we present significant results that survive Bonferroni 513 correction for the number of genes tested per tissue and for all 11 tissues. 514 515
Genetic correlation analyses 516
Post-GWAS genome-wide genetic correlation analysis of LD Score Regression 517 (LDSC) 63-65 using LDHub was conducted using all UK Biobank SNPs also found in 518
HapMap3 and included publicly available data from 224 published genome-wide 519 association studies, with a significance threshold after Bonferroni correction for all tests 520 performed (P <0.05/224 tests). LDSC estimates genetic correlation between two traits 521 from summary statistics (ranging from -1 to 1) using the fact that the GWAS effect-size 522 between case/control studies and quantitative traits, as well as within these trait types. 527
We performed partitioning of heritability using the 8 pre-computed cell-type regions, and 528 25 pre-computed functional annotations available through LDSC, which were curated 529 from large-scale robust datasets 63 . Enrichment both in the functional regions and in an 530 expanded region (+500bp) around each functional class was calculated in order to 531 prevent the estimates from being biased upward by enrichment in nearby regions. The 532 multiple testing threshold for the partitioning of heritability was determined using the 533 all SNPs, horizontal pleiotropy is (i) uncorrelated with SNP-risk factor associations and 545
(ii) has an average value of zero. MR-Egger assumes (i) but relaxes (ii) by explicitly 546 estimating the non-zero mean pleiotropy, and adjusting the causal estimate accordingly. 547
Estimation of the pleiotropy parameter means that the MR-Egger estimate is generally 548 far less precise than the IVW estimate. The weighted median approach is valid if less 549 than 50% of the weight is pleiotropic (i.e. no single SNP that contributes 50% of the 550 weight or a number of SNPs that together contribute 50% should be invalid because of 551 horizontal pleiotropy). Given these different assumptions, if all three methods are 552 broadly consistent this strengthens our causal inference. For all our MR analyses we 553 used two-sample MR, in which, for all 78 GWAS hits identified in this study for sleep 554 duration, we looked for the per allele difference in odds (binary outcomes) or means 555 (continuous) with outcomes from summary publicly available data in the MR-Base 556 platform. Results are therefore a measure of 'longer sleep duration' and sample 1 is UK 557 Biobank (our GWAS) and sample 2 a number of different GWAS consortia covering the 558 outcomes we explored (Supplementary Table 31,32) . The number of SNPs used in 559 each MR analysis varies by outcome from because of some SNPs (or proxies for them) 560 not being located in the outcome GWAS. Supplementary Table 28. A. B. Table 1 . A risk score of genetic variants for self-reported sleep duration (78 SNPs), self-reported short (27 SNPs) or long (8 SNPs) sleep duration associates with a) activity-monitor based measures of sleep fragmentation, timing and duration from 7 day accelerometry in the UK Biobank (n =85,499), b) self-reported sleep duration in the CHARGE study (n =47,180) and c) self-reported sleep duration in the EAGLE study (n =10,554). Genetic risk scores for sleep duration, short sleep and long sleep were tested using the weighted genetic risk score calculated by summing the products of the sleep trait risk allele count for all 78, 27, or 8 genome-wide significant SNPs multiplied by the scaled effect from the primary GWAS using the GTX package in R. Effect estimates (Beta or OR) are reported per each additional effect allele for sleep duration, short sleep, or long sleep. Abbreviations: CI=confidence interval, GRS=genetic risk score, OR=odds ratio. # Self-reported and varied by cohorts, typically: "How many hours of sleep do you usually get at night (or your main sleep period)?" * In all cohorts, except in GLAKU, child sleep duration was assessed by a single, parent-rated, open question, "How many hours does your child sleep per day including naps?" In GLAKU, parents were asked about the usual bed and rise times during school days, from which the total sleep duration could be estimated.
